CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
复制标题
CS055 (Chidamide/HBI-8000) 是一种新型组蛋白脱乙酰酶抑制剂，可诱导人白血病细胞 G1 期阻滞、ROS 依赖性细胞凋亡和分化
DOI：
10.1042/bj20111685
复制
发表时间：
2012-05-01
影响因子：
4.1
通讯作者：
Li, Wenhua
中科院分区：
文献类型：
--
作者：
Gong, Ke;Xie, Jia;Li, Wenhua
CS 055（Chidamide/HBI-8000）是一种新型苯甲酰胺类HDACi（组蛋白去乙酰化酶抑制剂），已在美国进入I期临床试验，在中国进入II/III期临床试验。在本研究中，我们研究了CS 055对人白血病细胞系和原发性髓系白血病细胞增殖、分化和凋亡的影响。结果表明，在低浓度下（
CS055 (Chidamide/HBI-8000) is a novel benzamide-type HDACi (histone deacetylase inhibitor), which has entered Phase I clinical trials in the U.S. and Phase II/III in China. In the present study, we investigated the effects of CS055 on proliferation, differentiation and apoptosis in human leukaemia cell lines and primary myeloid leukaemia cells. The results showed that at low concentrations (